Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation

Stefano Belli, Bruno Balbi, Ilaria Prince, Davide Cattaneo, Francesca Masocco, Sergio Zaccaria, Luca Bertalli, Francesco Cattini, Arianna Lomazzo, Francesca Dal Negro, Marica Giardini, Frits M.E. Franssen, Daisy J.A. Janssen, Martijn A. Spruit

Research output: Contribution to journalLetterpeer-review

Abstract

Introduction. The current use of lipid lowering therapies and the eligibility for proprotein convertase subtilisin/kexin-9 (PCSK9) inhibitors of patients surviving a myocardial infarction (MI) is poorly known. Methods. Using the data from two contemporary, nationwide, prospective, real-world registries of patients with stable coronary artery disease, we sought to describe the lipid lowering therapies prescribed by cardiologists in patients with a prior MI and the resulting eligibility for PCSK9 inhibitors according to the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) and the Italian regulatory agency (Agenzia Italiana del Farmaco; AIFA) criteria. The study cohort was stratified according to the following low-density lipoprotein cholesterol (LDL-C) levels at the time of enrolment: Results. Among the 3074 post-MI patients with LDL-C levels available, a target level of LDL-C < 70 mg/dl was present in 1186 (38.6%), while 1150 (37.4%) had LDL-C levels ranging from 70 to 99 mg/dl and the remaining 738 (24.0%) an LDL-C >= 100 mg/dl. A statin was prescribed more frequently in post-MI patients with LDL-C levels <70 mg/dl (97.1%) compared to the other LDL-C groups (p<0.0001). A low dose of statin was prescribed in 9.3%, while a high dose in 61.4% of patients. Statin plus ezetimibe association therapy was used in less than 18% of cases. In the overall cohort, 293 (9.8%) and 450 (22.2%) resulted eligible for PCSK9 inhibitors, according to ESC/EAS and AIFA criteria, respectively. Conclusions. Post-MI patients are undertreated with conventional lipid lowering therapies. A minority of post-MI patients would be eligible to PCSK9 inhibitors according to ESC/EAS guidelines and Italian regulatory agency criteria.
Original languageEnglish
Article number3856242
JournalThe European respiratory journal
Volume56
Issue number4
DOIs
Publication statusPublished - Oct 1 2020

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation'. Together they form a unique fingerprint.

Cite this